

24 November 2020

**ImmuPharma PLC**  
("ImmuPharma" or the "Company")

**Conversion of Convertible Security**

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that Lind Global Macro Fund, LP ("Lind") has converted \$355,112.50 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on 11 June 2020. The conversion price is 11p per share resulting in the issue by the Company of 2,504,982 new ordinary shares of 10p each in the Company ("New Ordinary Shares"). All of the convertible security issued to Lind has now been repaid or converted.

**New Ordinary Shares and Admission**

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank *pari passu* in all respects with the Company's existing issued ordinary shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange ("AIM") and Euronext Growth Brussels ("Admission"). It is anticipated that Admission to AIM will occur at 8.00am on or around Friday 27 November.

The New Ordinary Shares represent 1.00% of the Company's enlarged issued share capital.

**Total Shares in Issue**

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company's total issued share capital will consist of 250,221,297 Ordinary Shares with a nominal value of 10p each.

This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.

The allotment of the New Ordinary Shares is being made pursuant to existing authorities to allot shares and other relevant securities and to disapply pre-emption rights under section 551 of the Companies Act 2006, which the Directors were given at the Company's Annual General Meeting held on 18 June 2020. ***This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.***

For further information please contact:

|  |                       |
|--|-----------------------|
| <b>ImmuPharma PLC (<a href="http://www.immupharma.com">www.immupharma.com</a>)</b> | + 44 (0) 207 152 4080 |
| Tim McCarthy, Chairman   |                       |
| Dimitri Dimitriou, Chief Executive Officer   |                       |
| Lisa Baderon, Head of Investor Relations   | + 44 (0) 7721 413496  |

|  |                      |
|--|----------------------|
| <b>SPARK Advisory Partners Limited (NOMAD)</b> | +44 (0) 203 368 3550 |
| Neil Baldwin                                   |                      |

|  |                      |
|--|----------------------|
| <b>Stanford Capital Partners (Joint Broker)</b>    | +44 (0) 203 815 8880 |
| Patrick Claridge                                   |                      |
| John Howes   |                      |
| Bob Pountney                                       | +44 (0) 1483 413500  |
| <b>SI Capital (Joint Broker)</b>                   |                      |
| Nick Emerson                                       |                      |
| <b>4Reliance (Euronext Growth Listing Sponsor)</b> | +32 (0) 2 747 02 60  |
| Jean-Charles Snoy                                  |                      |
| <b>Degroof Petercam (Liquidity Provider)</b>       | +32 (0) 2 287 95 34  |
| Erik De Clippel                                    |                      |
| <b>Backstage Communication</b>                     |                      |
| Olivier Duquaine                                   | +32 (0) 477 504 784  |
| Gunther De Backer                                  | +32 (0) 475 903 909  |

## Notes to Editors

### About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.

For additional information about ImmuPharma please visit [www.immupharma.com](http://www.immupharma.com).

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.